plexiform neurofibroma NF1
Rare disease · 2022–2024
2decisions
1medicine
2carried consumer input
51individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| selumetinib Treatment of symptomatic, inoperable plexiform neurofibroma(s) in paediatric patients aged 2 years and over with neurofibromatosis type 1 (NF1). | Mar 2024 | Recommended with restriction | 22 individuals Tumour Foundation |
| selumetinib Treatment of symptomatic, inoperable plexiform neurofibroma(s) in paediatric patients with neurofibromatosis type 1 (NF1). | Nov 2022 | Not recommended | 29 individuals Tumour Foundation |
Who spoke
Tumour Foundation
What the PBS pays
$4M in government benefit over 2024–25, across 302 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| selumetinib | $4.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.